Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus Whole Brain Radiotherapy for HER2-positive breast cancer with brain metastases
2010-021191-29Phase 2Terminated
- Sponsor
- Roche
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer and brain metastases, sponsored by Roche. Primary endpoint: Brain objective response rate at cycle 7. Started Jun 2011; status: terminated.
02
Drugs
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2010-021191-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021191-29.